Paradromics

Paradromics is building a high data-rate brain-computer interface to provide technology solutions for people with neurological and brain-related conditions. The company's Connexus Direct Data Interface targets the highest-volume neural data acquisition of any implanted BCI in development, using microwire bundle technology. Paradromics received FDA Breakthrough Device Designation and raised $33M in Series A funding (2023), with additional investment from NEOM in 2025. The company's thesis is that the bottleneck in BCI is the amount of neural data that can be captured, not the implant procedure.